Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821951 · ClinicalTrials.gov registry record · Phase 1
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00821951: Completed Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Yale University.
NCT00821951 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Yale University. The registered enrollment target is 17 participants, below the 285-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00821951, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may enhance the effect of radiotherapy, and this study will seek to confirm this.
Primary Outcome
maximum tolerated dose of vorinostat when given concurrently with radiation
Conditions Studied
Interventions
- RADIATION Radiotherapy
- DRUG Vorinostat
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
What the finished NCT00821951 record still lists
NCT00821951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 285-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Radiotherapy is the first listed.
NCT00821951 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00821951 about?
NCT00821951 is a clinical study titled "Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer". This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T...
What is the current status of trial NCT00821951?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-05. Estimated completion is 2012-07.
What conditions does trial NCT00821951 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT00821951?
The interventions under investigation include: Radiotherapy (RADIATION), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00821951?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00821951 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00821951's enrollment target sits among peer trials
17 56th of 59 higher than 4 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia